Aptose to Present at 2020 RBC Capital Markets Global Healthcare Virtual Conference

Rhea-AI Summary

Aptose Biosciences, a clinical-stage biotechnology firm, will attend the RBC Capital Markets Global Healthcare Virtual Conference on May 20, 2020. Their presentation is scheduled from 3:40 to 4:05 pm EDT. The event will include investor meetings and a fireside chat format. Aptose focuses on developing personalized cancer therapies, notably two agents in clinical trials: CG-806, a first-in-class kinase inhibitor for hematologic malignancies, and APTO-253, targeting the MYC oncogene for acute myeloid leukemia.

SAN DIEGO and TORONTO, May 07, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the company will participate in and hold investor meetings at the RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20, 2020.

Conference Presentation Details:

Date:               Wednesday, May 20, 2020
Time:               3:40 – 4:05 pm EDT
Location:         Virtual, Fireside Chat
Webcast:         link

The webcast and presentation will be archived shortly after the live event and will be available on the Aptose website here. 

About Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies; APTO-253, the only clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). For further information, please visit www.aptose.com.

For further information, please contact:

40%; border-collapse:collapse !important;">

Aptose Biosciences Inc.	LifeSci Advisors, LLC
Greg Chow	Dan Ferry, Managing Director
Executive Vice President, CFO	617-535-7746
650-718-5028	Daniel@LifeSciAdvisors.com
gchow@aptose.com
SMP Communications
Susan Pietropaolo
201-923-2049
susan@smpcommunications.com

 

FAQ

When is Aptose's presentation at the RBC Capital Markets Global Healthcare Virtual Conference?

Aptose's presentation is scheduled for May 20, 2020, from 3:40 to 4:05 pm EDT.

What is the focus of Aptose Biosciences' clinical-stage products?

Aptose focuses on developing personalized therapies for oncology, particularly hematologic malignancies.

What are the investigational products being developed by Aptose?

Aptose is developing CG-806, a kinase inhibitor, and APTO-253, which targets the MYC oncogene.

Where can I find the webcast of Aptose's conference presentation?

The webcast will be archived on Aptose's website shortly after the live event.

What time will Aptose's presentation take place during the virtual conference?

The presentation will take place from 3:40 to 4:05 pm EDT.